HER2+ early breast cancers where shorter-course trastuzumab could be an option

(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news